PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Budesonide - Inflammatory bowel disease

PAD Profile : Budesonide - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, UC, IBD, protitis, procto sigmoiditis
Brand Names Include :
Budenofalk
Important Information :
Steroid safety considerations

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Foam enema
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
BNF NICE SPC
SA
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Please see the attached pathway which has been developed in conjunction with local specialists for the GP management of adult patients with known ulcerative colitis . 

13 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Budenofalk (budesonide) rectal foam as a treatment option for patients with active Ulcerative Colitis Budenofalk (budesonide) rectal foam will be considered GREEN on the traffic light system Primary care prescribers should consider switching patients to budesonide rectal foam and for all new patients to use budesonide rectal foam moving forwards.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.02. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More